Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trialJane C. Burns, Nichole Samuy, Adriana H. Tremoulet et al.|The Lancet Child & Adolescent Health|2021Cited by 113